Fixed Dose Triple Therapy in Severe Chronic Obstructive Pulmonary Disease in a Real World Setting
NCT ID: NCT03627858
Last Updated: 2021-11-29
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
149 participants
OBSERVATIONAL
2018-08-01
2020-08-03
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
This is an hypothesis generating study. No formal primary endpoint is defined; parameters are evaluated in an exploratory or descriptive manner.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
beclomethasone / formoterol / glycopyrronium
As this is a non-interventional study, all treatment decisions will be made at the discretion of the treating physician prior to enrolment in the study and during the entire period of the study. Treatment will be prescribed according to the product label in the summary of product characteristics.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patient is aged 40 years or older at time of initiation of Trimbow® treatment
* Patient is diagnosed with moderate or severe chronic obstructive pulmonary disease confirmed by spirometry (post-bronchodilation) based on the Global Initiative for chronic obstructive lung disease (GOLD) 2018 classification
* Patient treated with double inhalation or free triple therapy (using at least 2 devices) who are prescribed Trimbow®
Exclusion Criteria
* Ethanol anhydrous
* Hydrochloric acid
* Norflurane (propellant)
40 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Chiesi SA/NV
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Guy Brusselle, MD-PhD
Role: PRINCIPAL_INVESTIGATOR
University Ghent
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
ZNA Middelheim
Antwerp, , Belgium
Universitair Ziekenhuis Antwerpen
Antwerp, , Belgium
GZA Campus Sint-Vincentius
Antwerp, , Belgium
Hôpital Erasme
Brussels, , Belgium
UZ Brussel
Brussels, , Belgium
Grand Hôpital de Charleroi
Charleroi, , Belgium
Clinique Notre-Dame de Grâce ASBL Gosselies
Charleroi, , Belgium
UZ Gent
Ghent, , Belgium
AZ Groeninge
Kortrijk, , Belgium
CHR de la Citadelle
Liège, , Belgium
AZ Sint-Maarten
Mechelen, , Belgium
Hôpital André Vésale
Montigny-le-Tilleul, , Belgium
Clinique Saint-Luc Bouge
Namur, , Belgium
AZ Delta
Roeselare, , Belgium
Hospital Center De Wallonie Picarde
Tournai, , Belgium
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CHIESI_NIS_0001
Identifier Type: -
Identifier Source: org_study_id